Does Monoamine Oxidase Inhibitors Maois Interact with Ipratropium Bromide And Albuterol Sulfate?
CDI records a major classification for Monoamine Oxidase Inhibitors Maois and Ipratropium Bromide And Albuterol Sulfate. The stored summary is: Extreme caution advised; action of albuterol on cardiovascular system may be potentiated. Should not be used within 2 weeks of MAOi discontinuation. The mechanism involves potentiation of albuterol's cardiovascular effects. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
potentiation of albuterol's cardiovascular effects
What To Tell Your Doctor or Pharmacist
If you are taking Monoamine Oxidase Inhibitors Maois and your doctor is considering prescribing Ipratropium Bromide And Albuterol Sulfate (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider